IP Library Granted Patent US 7,053,194
Granted Patent B2
US 7,053,194 · App. 10/108,877 · Granted May 30, 2006

Compositions and methods for p53-mediated repression of gene expression

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,053,194
App. No.
10/108,877
Granted
May 30, 2006
Kind
B2
Abstract

Compositions and methods are provided for identifying novel therapeutic agents for the treatment of cancer and other cellular proliferative disorders.

Claims (38)

1. An isolated nucleic acid molecule comprising a Map4 promoter region, wherein said promoter region is contained in SEQ ID NO.1.

2. An expression vector comprising the nucleic acid molecule of claim 1 .

3. The vector of claim 2 , wherein said vector is an expression vector operably linked to a heterologous gene encoding a gene product.

4. The vector of claim 3 , wherein said heterologous gene is a reporter gene.

5. The vector of claim 3 , wherein said heterologous gene is selected from the group consisting of luciferase, secreted alkaline phosphatase, GFP and chloramphenicol acetyltransferase.

6. An isolated host cell transformed with the vector of claim 3 .

7. The host cell of claim 6 , wherein said host cell is a prokaryotic cell.

8. The host cell of claim 6 , wherein said host. cell is a eukaryotic cell.

9. The host cell of claim 8 which is a human cell.

10. The host cell of claim 8 which is a tumor cell.

11. An isolated nucleic acid molecule comprising a survivin promoter region, wherein said promoter region is contained in SEQ ID NO.2.

12. An expression vector comprising the nucleic acid molecule of claim 11 .

13. The vector of claim 12 , wherein said vector is an expression vector operably linked to a heterologous gene encoding a gene product.

14. The vector of claim 13 , wherein said heterologous gene is a reporter gene.

15. The vector of claim 14 , wherein said heterologous gene is selected from the group consisting of luciferase, secreted alkaline phosphatase, GFP and chloramphenicol acetyltransferase.

16. An isolated host cell transformed with the vector of claim 12 .

17. The host cell of claim 16 , wherein said host cell is a prokaryotic cell.

18. The host cell of claim 16 , wherein said host cell is a eukaryotic cell.

19. The host cell of claim 18 which is a human cell.

20. The host cell of claim 19 which is a tumor cell.

21. A minimal p53 repressible element having the sequence of SEQ ID NO: 3.

22. A DNA construct comprising the element of claim 21 .

23. An isolated nucleic acid molecule comprising the minimal p53 repressible element of claim 21 .

24. A vector comprising the nucleic acid molecule of claim 23 .

25. The vector of claim 24 , wherein said vector is an expression vector and said minimal p53 repressible element is operably linked to a heterologous gene encoding a gene product.

26. The expression vector of claim 25 , wherein said heterologous gene is a reporter gene.

27. The expression vector of claim 26 , wherein said heterologous gene is selected from the group consisting of luciferase, secreted alkaline phosphatase, green fluorescent protein, and chloramphenicol acetyltransferase.

28. An isolated host cell transformed with the expression vector of claim 25 .

29. The host cell of claim 28 , wherein said host cell is a prokaryotic cell.

30. The host cell of claim 28 , wherein said host cell is a eukaryotic cell.

31. The host cell of claim 30 which is a human cell.

32. The host cell of claim 30 which is a tumor cell.

33. A process for producing a host cell containing a heterologous gene operably linked to the minimal p53 repressible element of claim 21 which comprises:

a) transfecting a cell with an expression vector comprising said heterologous gene operably linked to the minimal p53 repressible element of claim 21 , said expression vector operably comprising a selectable marker gene; and

b) selecting transformed host cells on the basis of said transformed cells containing a heterologous gene operably linked to the minimal p53 repressible element of claim 21 .

34. The expression vector of claim 25 , wherein said heterologous gene is the herpes simplex virus thymidine kinase gene.

35. The vector of claim 24 , wherein said minimal p53 repressible element is operably linked to a sequence encodingfor an antisense molecule.

36. The vector of claim 35 , wherein said antisense molecule is specific for a nucleic acid encoding for a protein selected from the group consisting of bcl-2, survivin, and P-glycoprotein.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2020
From: THE FOX CHASE CANCER CENTER FOUNDATION
To: THE INSTITUTE FOR CANCER RESEARCH
Reel/Frame 053562/0938 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2004
From: MURPHY, MAUREEN E.
To: FOX CHASE CANCER CENTER
Reel/Frame 015706/0430 →